Loading
An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.
ALPHAMEDIX-02 (Sanofi/Orano Med/RadioMedix, October 2025): met all primary endpoints; ORR 54.3% in PRRT-naive patients with ~70-75% progression-free at about 3 years, and durable disease control in PRRT-exposed patients (~83% progression-free at 18 months). Breakthrough Therapy designation 2024. Sanofi acquired global rights (2024); registrational strategy under discussion. Supply relies on Orano Med's 212Pb generators.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
DOTAMTATE (SSTR2 agonist) chelating 212Pb, which decays via 212Bi to emit an alpha particle at the tumour cell. Connects to Somatostatin receptor 2.
1.212Pb-DOTAMTATE binds Somatostatin receptor 2 on the cancer cell or is taken up by it.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-09-12 | RadioMedix to Sanofi AlphaMedix (lead-212 DOTAMTATE), targeted alpha therapy for neuroendocrine tumours | Licence | not disclosed | not disclosed | source |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"212Pb-DOTAMTATE" OR ABSTRACT:"212Pb-DOTAMTATE" OR TITLE:"AlphaMedix" OR ABSTRACT:"AlphaMedix") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 212Pb-DOTAMTATE, not a curated reading list.
Shares Beta PRRT → alpha PRRT, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Targeted alpha therapy.
Shares ALPHAMEDIX-02, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Targeted alpha therapy.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.